NCT07940439
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Adverse Events (AEs)
Timeframe: From Day 1 to 40 days after the last dose.
Dose-limiting toxicity (DLT)
Timeframe: From Day 1 to 12 months.
Maximum tolerated dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended dose for Phase II clinical studies (RP2D)
Timeframe: From Day 1 to 12 months.
Secondary (4)
Progression free survival (PFS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)
Arms and interventions
HRS-9308 Dose 1 GroupExperimental
HRS-9308, with Dose 1.
HRS-9308 Dose 2 GroupExperimental
HRS-9308, with Dose 2.
HRS-9308 Dose 3 GroupExperimental
HRS-9308, with Dose 3.
HRS-9308 Dose 4 GroupExperimental
HRS-9308, with Dose 4.
HRS-9308 Dose 5 GroupExperimental
HRS-9308, with Dose 5.
Drugs: HRS-9308 Tablet
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China